https://pipelinereview.com/Innovent-Announces-Phase-2-Clinical-Study-of-Higher-dose-9-mg-Mazdutide-IBI362-in-Chinese-Adults-with-Obesity-Achieved-the-24-Week-Primary-Endpoint/